Recommendations from the Spanish Oncology Genitourinary Group for the treatment of metastatic renal cancer
Por:
Bellmunt, J, Calvo, E, Castellano, D, Climent, MA, Esteban, E, del Muro, XG, Gonzalez-Larriba, JL, Maroto, P, Trigo, JM
Publicada:
1 mar 2009
Resumen:
For almost the last two decades, interleukin-2 and interferon-alpha have been the only systemic treatment options available for metastatic renal cell carcinoma. However, in recent years, five new targeted therapies namely sunitinib, sorafenib, temsirolimus, everolimus and bevacizumab have demonstrated clinical activity in these patients. With the availability of new targeted agents that are active in this disease, there is a need to continuously update the treatment algorithm of the disease. Due to the important advances obtained, the Spanish Oncology Genitourinary Group (SOGUG) has considered it would be useful to review the current status of the disease, including the genetic and molecular biology factors involved, the current predicting models for development of metastases as well as the role of surgery, radiotherapy and systemic therapies in the early- or late management of the disease. Based on this previous work, a treatment algorithm was developed.
Filiaciones:
Bellmunt, J:
Hosp Mar, Med Oncol Serv, Barcelona 08003, Spain
Calvo, E:
Hosp Valle De Hebron, Med Oncol Serv, Barcelona, Spain
Castellano, D:
Hosp 12 Octubre, E-28041 Madrid, Spain
Climent, MA:
Inst Valenciano Oncol, Med Oncol Serv, Valencia, Spain
Esteban, E:
Hosp Univ Cent Asturias, Med Oncol Serv, Oviedo, Spain
del Muro, XG:
Inst Catala Oncol, Med Oncol Serv, Barcelona, Spain
Gonzalez-Larriba, JL:
Hosp Clin San Carlos, Med Oncol Serv, Madrid, Spain
Maroto, P:
Hosp Santa Creu & Sant Pau, Med Oncol Serv, Barcelona, Spain
Trigo, JM:
Hosp Virgen Victoria, Med Oncol Serv, Malaga, Spain
|